Myotoxic effects of clenbuterol in the rat heart and soleus muscle

Journal of Applied Physiology

Volumn 93, Issue 5, 2002, Pages 1824-1832

  Burniston, Jatin G ^a   Ng, Yeelan ^a   Clark, William A ^c   Colyer, John ^b   Tan, Lip bun ^b   Goldspink, David F ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NONE

Author keywords

Anabolic adrenergic agonist; Cardiomyocytes; Immunohistochemistry; Necrosis; Sympathomimetic; adrenergic antagonists

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLENBUTEROL; MYOSIN ANTIBODY;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOCARDIUM; HEART MUSCLE; HEART MUSCLE NECROSIS; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE INJURY; NONHUMAN; PRIORITY JOURNAL; RAT; SOLEUS MUSCLE; TOXICITY TESTING;

EID: 0036872642     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00139.2002     Document Type: Article

References (38)

1. Bakker AJ, Head SI, Wareham AC, and Stephenson DG. Effect of clenbuterol on sarcoplasmic reticulum function in single skinned mammalian skeletal muscle fibers. Am J Physiol Cell Physiol 274: C1718-C1726, 1998.
2. Beau SL, Tolley TK, and Saffitz JE. Heterogeneous transmural distribution of β-adrenergic receptor subtypes in failing human hearts. Circulation 88: 2501-2509, 1993.
3. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, and Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65: 657-670, 1989.
4. Bruera E. Pharmacological treatment of cachexia: any progress? Support Care Cancer 6: 109-113, 1998.
5. Chen KD and Alway SE. A physiological level of clenbuterol does not prevent atrophy or loss of force in skeletal muscle of old rats. J Appl Physiol 89: 606-612, 2000.
6. 2-adrenoceptor activation. Am J Physiol Endocrinol Metab 263: E50-E56, 1992.
7. Cooke GA, Marshal P, Al-Timman JK, Wright DJ, Riley R, Hainsworth R, and Tan LB. Physiological cardiac reserve: development of a non-invasive method and first estimates in man. Heart 79: 289-294, 1998.
8. Dimassi N, Bril A, Autissier N, Bralet J, and Rochette L. Relations between reperfusion arrhymias and myocardial norepinephrine and accumulation of calcium in the rat. Cardioscience 3: 7-12, 1992.
9. 2-agonist drug clenbuterol on taurine levels in heart and other tissues in the rat. Amino Acids (Vienna) 15: 13-25, 1998.
10. Duchanie D. Underground Steroid Handbook (II) Update: 1992. Venice, CA: HLR Technical Books, 1992.
11. Duncan ND, Williams DA, and Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Colch) 98: 339-347, 2000.
12. Frances H, Diquet B, Goldsmidt P, and Simon P. Tolerance to or facilitation of pharmacological effects induced by chronic treatment with the β-adrenergic stimulant clenbuterol. J Neural Transm Suppl 62: 65-76, 1985.
13. Goldstein DR, Dobbs T, Krull B, and Plumb VJ. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J 91: 780-784, 1998.
14. Hayes A and Williams DA. Contractile properties of clenbuterol-treated mdx muscle are enhanced by low-intensity swimming. J Appl Physiol 82: 435-439, 1997.
15. Hayes A and Williams DA. Examining potential drug therapies for muscular dystrophy utilizing the dy/dy mouse: I. Clenbuterol. J Neurol Sci 157: 122-128, 1998.
16. Huxtable RJ. Physiological actions of taurine. Physiol Rev 72: 101-163, 1992.
17. Ingalls CP, Barnes WS, and Smith SB. Interaction between clenbuterol and run training: effects on exercise performance and MLC isoform content. J Appl Physiol 80: 795-801, 1996.
18. Jackson MJ, Jones DA, and Edwards RHT. Experiment skeletal muscle damage: the nature of the calcium-activated degenerative processes. Eur J Clin Invest 14: 369-374, 1984.
19. Kendall MJ and Haffner CA. The Acute Unwanted Effects of β-2 Receptor Agonist Therapy. Boca Raton, FL: CRC, 1993, p. 163-199.
20. Lynch GS, Hinkle RT, and Faulkner JA. Year-long clenbuterol treatment of mice increases mass, but not specific force or normalized power, of skeletal muscles. Clin Exp Pharmacol Physiol 26: 117-120, 1999.
21. Lynch GS, Hinkle RT, and Faulkner JA. Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment. Neuromuscul Disord 11: 192-196, 2001.
22. Majno G and Joris I. Apoptosis, oncosis, and necrosis: an overview of cell death. Am J Pathol 146: 3-15, 1995.
23. Maltin C, Delday M, Watson J, Heys S, and Nevison I. Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Colch) 84: 651-654, 1993.
24. Mann DL, Kent RL, Parsons B, and Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85: 790-804, 1992.
25. McRae JC, Skene PA, Connell A, Buchan V, and Lobley GE. The action of the beta-agonist clenbuterol on protein and energy metabolism in fattening wether lambs. Br J Nutr 59: 457-465, 1988.
26. Murphy RJL, Beliveau L, Seburn KL, and Gardiner PF. Clenbuterol has a greater influence on untrained than on previously trained skeletal muscle in rats. Eur J Appl Physiol 73: 304-310, 1996.
27. Ng Y, Goldspink DF, Burniston JG, Clark WA, Colyer J, and Tan LB. Characterization of isoprenaline myotoxicity on slow-twitch versus cardiac muscle. Int J Cardiol. In press.
28. Prather ID, Brown DE, North P, and Wilson JR. Clenbuterol: substitute for anabolic steroids? Med Sci Sports Exerc 27: 1118-1121, 1995.
29. Rehfield C, Schaderlet R, Weikard R, and Reichel K. Effect of clenbuterol on growth, carcase and skeletal muscle characteristics in broiler chickens. Br Poult Sci 38: 366-373, 1997.
30. Rothwell NJ, Stock MJ, and Sudera DK. Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the β2-adrenoceptor agonist clenbuterol. Br J Pharmacol 90: 601-607, 1987.
31. Schane FAX, Kane AB, Young EE, and Farber JL. Calcium dependence of toxic cell death: a final common pathway. Science 206: 700-702, 1979.
32. Tan L, Jalil JE, Pick R, Janicki JS, and Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 69: 1185-1195, 1991.
33. Tofukkji M, Nakeame T, Murata S, Yanai K, Ohmi M, and Tabayashi K. Altered distribution and density of myocardial beta-adrenoceptors during acute rejection in rats. Transplantation 69: 1572-1577, 2000.
34. Trump BF, Berezesky IK, Chang SH, and Phelps PC. The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol 25: 82-88, 1997.
35. Von Deutsch DA, Abukhalf IA, Wineski LE, Aboul-Enein HY, Pitts SA, Parks BA, Oster RA, Paulsen DF, and EPD. Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers. Chirality 12: 637-648, 2000.
36. Waterfield CJ, Jairath M, Asker DS, and Timbrell JA. The biochemical effects of clenbuterol: with particular reference to taurine and muscle damage. Eur J Pharmacol 293: 141-149, 1995.
37. Williams SG, Cooke GA, Wright DJ, Parsons WJ, Riley RL, Marshal P, and Tan LB. Peak exercise cardiac power output: a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure. Eur Heart J 22: 1496-1503, 2001.
38. Yamamoto I, Iwata K, and Nakashima M. Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. J Pharmacobio-Dyn 8: 385-391, 1985.